 |
|
|
December 2004 News Archive GlaxoSmithKline, Vanderbilt, and FDA to Collaborate in Evaluating Drug-Induced Long QT Syndrome Posted by Mark First Genetic Trust has announced that the FDA, Vanderbilt University Medical Center, and GlaxoSmithKline, will take part in an innovative clinical research effort using enTRUST genetic banking and research technology to study the genetic basis for drug-induced (acquired) Long QT syndrome, a well-known side effect of many different classes of drugs. Patients who have been diagnosed with drug-induced Long QT syndrome are encouraged to participate in the study. For more information and to read the entire press release click here. Long QT Screening in Newborns Posted by Mark Data collected during a recent study by Dr. Peter Schwartz (University of Pavia, Italy) suggests that early EKG screening may be an effective and cost efficient tool for identifying infants with Long QT syndrome. Based partially on the results of this study, the Italian Parliament is considering legislation to offer EKG screenings to newborns. To read the full article published in New Scientist Magazine click here. The contents of the Long-QT-Syndrome.com Site, such as text, graphics, images and all other material contained on Long-QT-Syndrome.com are for informational purposes only. The contents were not written by a practicing medical doctor/physician and may not be correct. The content within Long-QT-Syndrome.com is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Long-QT-Syndrome.com Site! |
|||||
 |
||||||
